SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
Constanze Schneider(Goethe University Frankfurt), Jindřich Činátl(Goethe University Frankfurt), Wolfgang Hartmann(University Hospital Münster), Lena Stegmann(Goethe University Frankfurt), Thomas Oellerich(Goethe University Frankfurt), Veit Hornung(University of Massachusetts Chan Medical School), Hanibal Bohnenberger(Universitätsmedizin Göttingen), Wolfgang E. Berdel(University Hospital Münster), Philipp Ströbel(Universitätsmedizin Göttingen), Sarah-Marie Schwarz(Goethe University Frankfurt), Federico Comoglio(University of Cambridge), Dominique Thomas(Goethe University Frankfurt), Margarethe Martin(Goethe University Frankfurt), Nerea Ferreirós(Goethe University Frankfurt), Eva Wardelmann(University Hospital Münster), Julian J.K. Lohmeyer(Goethe University Frankfurt), Christoph Schliemann(University Hospital Münster), Martin Michaelis(University of Kent), Gerd Geißlinger(Goethe University Frankfurt), Alexander F. Yakunin(Bangor University), Oliver T. Keppler(German Center for Infection Research), Robert Flick(University of Toronto), Hubert Serve(Goethe University Frankfurt), Hanna‐Mari Baldauf(Goethe University Frankfurt), Martin‐Leo Hansmann(Goethe University Frankfurt), Lars Kaderali(Universitätsmedizin Greifswald), Anjali Cremer(Goethe University Frankfurt)
Cited by 185
Related Papers
Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome
|New England Journal of Medicine|2003|4.8k
An updated evolutionary classification of CRISPR–Cas systems
|Nature Reviews Microbiology|2015|2.6k
Evolution and classification of the CRISPR–Cas systems
|Nature Reviews Microbiology|2011|2.5k
Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants
|Nature Reviews Microbiology|2019|2.5k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k